Get started
Author

Frédéric François Lehmann

Observed names: F Lehmann, F. F. Lehmann, F. Lehmann, F.F. Lehmann, FRÉDÉRIC LEHMANN, Frederic F Lehmann, Frederic F. Lehmann, Frederic Lehmann, Frédéric Lehmann, Frédéric F Lehmann, Frédéric F. Lehmann, Frédéric Lehmann, Lehmann, Frederic F
Institution: Celyad (Belgium)
Observed institutions: European Organisation for Research and Treatment of Cancer, Université Libre de Bruxelles, Ludwig Cancer Research, Johannes Gutenberg University Mainz, Universitair Ziekenhuis Leuven, Institut Jules Bordet, Institut Gustave Roussy, Erasmus MC, Centre Hospitalier Universitaire de Lille, University Medical Center of the Johannes Gutenberg University Mainz, GlaxoSmithKline (Belgium), Marqués de Valdecilla University Hospital, Celyad (Belgium), GlaxoSmithKline (United States), Ludwig Cancer Research, European Organisation for Research and Treatment of Cancer, Hospital Universitario Central de Asturias, Lungenklinik Hemer, GlaxoSmithKline (Switzerland), Erasmus MC Cancer Institute, Daniel den Hoed Kliniek, Gdańsk Medical University, Institut Curie, UCLouvain, KU Leuven
ORCID: 0000-0002-6409-1904
Observed ORCID: 0000-0002-6409-1904
OpenAlex ID: A5006704059
Characterization of an Antigen That Is Recognized on a Melanoma Showing Partial HLA Loss by CTL Expressing an NK Inhibitory Receptor
1997 · Hideyuki Ikeda, Bernard Lethé, et al. · Immunity · 776
PDF
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
2013 · Fernando Ulloa-Montoya, Jamila Louahed, et al. · Journal of Clinical Oncology · 445
PDF
A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma.
1995 · P G Coulie, F Lehmann, et al. · Proceedings of the National Academy of Sciences · 437
Phase I Trial of Autologous CAR T Cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma
2018 · Susanne H. Baumeister, Joana Murad, et al. · Cancer Immunology Research · 339
Adjuvant MAGE-A3 Immunotherapy in Resected Non–Small-Cell Lung Cancer: Phase II Randomized Study Results
2013 · Johan Vansteenkiste, Marcin Zielinski, et al. · Journal of Clinical Oncology · 325
PDF
Molecular Imaging and Biological Evaluation of HuMV833 Anti-VEGF Antibody: Implications for Trial Design of Antiangiogenic Antibodies
2002 · G. C. Jayson, J. Zweit, et al. · JNCI Journal of the National Cancer Institute · 259
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
2013 · Wim H.J. Kruit, Stefan Suciu, et al. · Journal of Clinical Oncology · 236
Differences in the antigens recognized by cytolytic T cells on two successive metastases of a melanoma patient are consistent with immune selection
1995 · Frédéric Lehmann, Marie Marchand, et al. · European Journal of Immunology · 223
Genes encoding tumor-specific antigens are expressed in human myeloma cells.
1999 · N van Baren, F Brasseur, et al. · PubMed · 195
Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC)
2007 · J. Vansteenkiste, M. Zielinski, et al. · Journal of Clinical Oncology · 151
Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate
2005 · Margarita Salcedo, Nadège Bercovici, et al. · Cancer Immunology Immunotherapy · 145
Precursor frequency analysis of human cytolytic T lymphocytes directed against autologous melanoma cells
1992 · Pierre G. Coulie, Michel Somville, et al. · International Journal of Cancer · 134
CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial
2023 · David A Sallman, Tessa Kerre, et al. · The Lancet Haematology · 111
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
2012 · Erika Hamilton, Kimberly Blackwell, et al. · Journal of Translational Medicine · 98
PDF
Safety and Immunogenicity of the PRAME Cancer Immunotherapeutic in Patients with Resected Non–Small Cell Lung Cancer: A Phase I Dose Escalation Study
2016 · Jean-Louis Pujol, Tommaso De Pas, et al. · Journal of Thoracic Oncology · 92
PDF
NKG2D-based chimeric antigen receptor therapy induced remission in a relapsed/refractory acute myeloid leukemia patient
2018 · David A. Sallman, Jason Brayer, et al. · Haematologica · 82
PDF
Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study
2016 · R. Gutzmer, L. Rivoltini, et al. · ESMO Open · 77
Chimeric Antigen Receptor-T Cells for Targeting Solid Tumors: Current Challenges and Existing Strategies
2019 · Lorraine Springuel, Caroline Lonez, et al. · BioDrugs · 70
PDF
Safety and Immunogenicity of MAGE-A3 Cancer Immunotherapeutic with or without Adjuvant Chemotherapy in Patients with Resected Stage IB to III MAGE-A3-Positive Non-Small-Cell Lung Cancer
2015 · Jean-Louis Pujol, Johan F. Vansteenkiste, et al. · Journal of Thoracic Oncology · 64
PDF
The Majority of Autologous Cytolytic T-Lymphocyte Clones Derived from Peripheral Blood Lymphocytes of a Melanoma Patient Recognize an Antigenic Peptide Derived from Gene Pmel17/gp100
1996 · Hassane Zarour, Charles De Smet, et al. · Journal of Investigative Dermatology · 59
PDF
Transient expansion of peptide-specific lymphocytes producing IFN-γ after vaccination with dendritic cells pulsed with MAGE peptides in patients with mage-A1/A3-positive tumors
2001 · M Toungouz, M Libin, et al. · Journal of Leukocyte Biology · 57
Genes Coding for Tumor Antigens Recognized by Human Cytolytic T Lymphocytes
1993 · Pierre G. Coulie, Patrick Weynants, et al. · Journal of Immunotherapy · 57
Human T cell lines and clones respond to IL-9
1993 · F A Houssiau, J C Renauld, et al. · The Journal of Immunology · 55
Manufacturing development and clinical production of NKG2D chimeric antigen receptor–expressing T cells for autologous adoptive cell therapy
2018 · Joana M. Murad, Susanne H. Baumeister, et al. · Cytotherapy · 53
Phase I investigation of recombinant anti-human vascular endothelial growth factor antibody in patients with advanced cancer
2005 · Gordon C. Jayson, Clive Mulatero, et al. · European Journal of Cancer · 53
Works count: 85
Citation count: 5,384
H-index: 32
I10-index: 50
Year
Topic
Type